Home | Log in or Sign Up for full access | Tracked Organizations | Recent Tracked Activities

Recent Activities

Activities between Nov. 15, 2024, 7:51 p.m. and Nov. 22, 2024, 7:51 p.m. from: Vaccine Business.

Click on a document link to see the original source document. Click on the name of an organization to see more organization linkages and timelines.


Novartis, Ratio sign radiopharmaceutical pact to the tune of $745M biobucks

Document Date: Nov. 18, 2024, 1 p.m. / Source: Fierce Biotech
Activity Class: PartnershipActivity / Region: Boston
Partnership: Document Extract: Novartis, Ratio sign radiopharmaceutical pact to the tune of $ 745M biobucks. Novartis is adding another radiopharmaceutical program to its collection, penning a deal worth $ 745 million in biobucks for rights to a cancer candidate from Ratio Therapeutics. Boston - based biotech Ratio and Novartis will work together researching and selecting a somatostatin receptor 2 (SSTR2) -targeting development candidate, according to a Nov. 18 release. From there, Novartis will take on the rest of the responsibilities around the asset, including further development and potential commercialization activities. The worldwide licensing agreement will leverage Ratio's radioligand tech platforms, which are designed to develop fit-for-purpose radiopharmaceuticals for therapy and imaging.
Document Source: https://www.fiercebiotech.com/biotech/novartis-ratio-sign-radiopharmaceutical-pact-tune-745m-biobucks (archive.org page / archive.org listing)


Alexandria Real Estate Equities, Inc. Announces Long-Term 258,581 RSF Lease With Longstanding Tenant Vaxcyte, Inc. at the Alexandria Center for Life Science - San Carlos Mega Campus

Document Date: Nov. 21, 2024, 9:10 p.m. / Source: PR Newswire
Activity Class: PartnershipActivity
Partnership: Document Extract: PASADENA, Calif., Nov. 21, 2024 /PRNewswire/ - Alexandria Real Estate Equities, Inc. (NYSE: ARE) , the first, preeminent, longest-tenured and pioneering owner, operator and developer of collaborative mega campuses in AAA life science innovation cluster locations, today announced that it executed a 10-year lease with Vaxcyte, Inc., a clinical-stage biopharmaceutical company working to protect humankind from the consequences of bacterial diseases, for a total of 258,581 RSF at 825 Industrial Road on the Alexandria Center® for Life Science - San Carlos mega campus in the San Francisco Bay Area. The lease includes new space as well as an extension of the lease term for its existing space. Alexandria Center® for Life Science - San Carlos mega campus. Courtesy of Alexandria Real Estate Equities, Inc. (PRNewsfoto/Alexandria Real Estate Equities, Inc. ) Vaxcyte has been an anchor tenant at the Alexandria Center for Life Science - San Carlos since it opened in 2021.
Document Source: https://www.prnewswire.com/news-releases/alexandria-real-estate-equities-inc-announces-long-term-258-581-rsf-lease-with-longstanding-tenant-vaxcyte-inc-at-the-alexandria-center-for-life-science--san-carlos-mega-campus-302312240.html (archive.org page / archive.org listing)


Surendralal Karsanbhai Elected to Merck Board of Directors

Document Date: Nov. 22, 2024, 11:30 a.m. / Source: Business Wire
Activity Class: RoleActivity / Type: Starting / Region: Canada, United States
Role: Person: Organization: Document Extract: Merck (NYSE: MRK) , known as MSD outside of the United States and Canada, today announced that Surendralal L. "Lal" Karsanbhai, president and chief executive officer, Emerson Electric Co. (NYSE: EMR) , will join Merck's board of directors effective January 1, 2025.
Document Source: https://www.businesswire.com/news/home/20241122809362/en/Surendralal-Karsanbhai-Elected-to-Merck-Board-of-Directors (archive.org page / archive.org listing)

Archive.org page links will work if the page has already been archived by archive.org, but we can't guarantee which pages archive.org has archived so far.

Treat sameAsNameOnly relationship as same? Yes (Turn Off)

Site Stats | About (includes privacy and cookie notices)
(c) by 1145, 2023-2024. Data licensed under the Open Database License. Please send an email if you need a non-share-alike license and/or you need API access.